Research Information System
The Eurasian Journal of Medical Advances, vol.3, no.3, pp.88-104, 2024 (Peer-Reviewed Journal)
The advancement of immunotherapy has changed cancer treatment. Immune checkpoint inhibitors (ICIs) are one of the
groundbreaking immunotherapies that have offered patients with advanced cancer new optimism by utilizing the immune system's innate ability to fight cancer with amazing success. Nevertheless, this exceptional approach has drawbacks, including the range of immune-related adverse events (irAEs) that can arise due to ICI therapy. IrAEs that impact
various parts and systems of the body can be particularly problematic, and can be difficult to identify and manage. Neurological side effects of ICIs are of particular interest, as they may vary from minor sensory issues to possibly fatal neuroinflammatory reactions. The purpose of this review is to elucidate the peculiarities of neurological immune-related adverse
events (n-irAEs) associated with ICIs and to provide a complete overview of the various facets of ICI therapy by exploring
the mechanisms, clinical manifestations, and management strategies of n-irAEs. Furthermore, it is crucial to emphasize
the importance of caution, early recognition, and collaboration between oncologists and neurologists to optimize patient
outcomes while overcoming the challenges posed by these enigmatic neurologic complications.